Drug intelligence / Profile preview

CCX587

Development stage: Preclinical
Lead developer: Amgen
Modality: Small Molecules
Administration: Oral

Overview

**CCX587** is an orally bioavailable small molecule antagonist of the C5a receptor (C5aR), developed by ChemoCentryx for autoimmune and inflammatory diseases driven by Th17 cells. It selectively blocks C5aR to inhibit neutrophil activation, migration, chemoattraction, and vascular adhesion implicated in conditions like inflammatory bowel disease. Initially explored for ulcerative colitis targeting CCR6-related pathways, its development status reflects early-stage evaluation within ChemoCentryx's chemokine receptor portfolio.[4][5][10]

Targets

C5AR1 (Complement C5a receptor 1)

Beyond the preview

Go deeper on CCX587.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CCX587.

Explore the full profile